don't need tickbite, just blood transfusion (babesia)

Discussion in 'Lyme Disease Archives' started by victoria, Jul 18, 2009.

  1. victoria

    victoria New Member


    Laura Tonnetti, Anne F. Eder, Beth Dy, Jean Kennedy, Patricia Pisciotto, Richard J. Benjamin, and David A. Leiby

    Transfusion, Published Online: 16 Jul 2009



    BACKGROUND: Babesia microti, the primary cause of human babesiosis in
    the United States, is an intraerythrocytic parasite endemic to the
    Northeast and upper Midwest. Published studies indicate that B. microti
    increasingly poses a blood safety risk. The American Red Cross
    Hemovigilance Program herein describes the donor and recipient
    characteristics of suspected transfusion-transmitted B. microti cases
    reported between 2005 and 2007.

    STUDY DESIGN AND METHODS: Suspected transfusion-transmitted Babesia
    infections were reported by transfusion services or were discovered
    through recipient-tracing investigations of prior donations from donors
    with a positive test for B. microti in a serologic study. Follow-up
    samples from involved donors were tested by Babesia-specific
    immunofluorescence assay, Western blot, and/or real-time polymerase
    chain reaction analysis.

    RESULTS: Eighteen definite or probable B. microti infections, including
    five fatalities, were identified in transfusion recipients, 16 from
    hospital-reported cases and two through serologic lookback studies.
    Thirteen recipients were 61 to 84 years old and two were 2 years old or
    younger. Two recipients had sickle cell disease and four were known to
    be asplenic, including one with sickle cell disease. Seventeen
    antibody-positive donors were implicated; 11 (65%) were residents in
    Babesia-endemic areas, while four (24%) nonresident donors had a history
    of travel to endemic areas.

    CONCLUSIONS: Transfusion-transmitted B. microti can be a significant
    cause of transfusion-related morbidity and mortality, especially in
    infant, elderly, and asplenic blood recipients. These data demonstrate
    the need for interventions, in both endemic and nonendemic areas of the
    United States, to reduce patient risk.